Risk factors and characteristics of hospitalized COVID-19 patients in Jordan

References

1. 1.↵
   World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19. [Updated2023 March 11; Cited 2023 Jul 3]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
2. 2.↵
   1. Wang Y,
   2. Wang Y,
   3. Chen Y,
   4. Qin Q

   . Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020; 92: 568–576.

   OpenUrlPubMed
3. 3.
   1. Gao Z,
   2. Xu Y,
   3. Sun C,
   4. Wang X,
   5. Guo Y,
   6. Qiu S, et al.

   A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect 2021; 54: 12–16.

   OpenUrl
4. 4.↵
   1. Wang Y,
   2. Liu Y,
   3. Liu L,
   4. Wang X,
   5. Luo N,
   6. Ling L

   . Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis 2020; 221: 1770–1774.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Garg S,
   2. Kim L,
   3. Whitaker M,
   4. O’Halloran A,
   5. Cummings C,
   6. Holstein R, et al.

   Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 458–464.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Chen N,
   2. Zhou M,
   3. Dong X,
   4. Qu J,
   5. Gong F,
   6. Han Y, et al.

   Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 5070–513.

   OpenUrl
7. 7.↵
   Prime Minister’s website. Defense orders notifications [Updated Cited 2023 June 3]. Available from: https://www.pm.gov.jo/AR/List/%d8%a8%d9%84%d8%a7%d8%ba%d8%a7%d8%aa_%d8%a3%d9%88%d8%a7%d9%85%d8%b1_%d8%a7%d9%84%d8%af%d9%81%d8%a7%d8%b9
8. 8.↵
   World Health Organization. Tracking SARS-CoV-2 variants; 2021 [Updated 2023; Cited 2023 July 3]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
9. 9.↵
   1. Vahey GM,
   2. McDonald E,
   3. Marshall K,
   4. Martin SW,
   5. Chun H,
   6. Herlihy R, et al.

   Colorado investigation team. Risk factors for hospitalization among persons with COVID-19-Colorado. PLoS One 2021; 16: e0256917.

   OpenUrlPubMed
10. 10.↵
    World Health Organization. WHO: Strengthened response to cardiovascular diseases. [Updated 20 May 2022; Cited 2023 June 3]. https://jordan.un.org/en/183019-strengthened-response-cardiovascular-diseases
11. 11.↵
    1. Liabeuf S,
    2. Moragny J,
    3. Bennis Y, et al.

    Association between renin-angiotensin system inhibitors and COVID-19 complications. Eur Heart J Cardiovasc Pharmacother 2020: pvaa062.
12. 12.↵
    1. Wilcox CR,
    2. Islam N,
    3. Dambha-Miller H

    . Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study [Erratum in: BMJ Open Respir Res. 2021; 8] [: PMID: 33664123; PMCID: PMC7934200]. BMJ Open Respir Res 2021; 8: e000857.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    World Health Organization. WHO Coronavirus Disease (COVID-19). [Updated 2023; Cited 2023 June 28]. Available from: https://covid19.who.int/
14. 14.↵
    Public Health England. Coronavirus (COVID-19) in the UK. [Updated 2023; Cited 2023 February 28]. Available from: https://coronavirus.data.gov.uk/details/healthcare?areaType=overview&areaName=United%20Kingdom
15. 15.↵
    Statista. Median age of the population in the United Kingdom from 1950 to 2021 (in years). [Updated 2023. Cited 2023 June 3]. Available from: https://www.statista.com/statistics/281288/median-age-of-the-population-of-the-uk/
16. 16.↵
    1. Turan O,
    2. Mirici A,
    3. Duru Akçalı S,
    4. Turan PA,
    5. Batum Ö,
    6. Şengül A, et al.

    Characteristics of hospitalised COVID-19 patients and parameters associated with severe pneumonia. Int J Clin Pract 2021; 75: e14786.

    OpenUrl
17. 17.↵
    1. Ousseiran ZH,
    2. Fares Y,
    3. Chamoun WT

    . Neurological manifestations of COVID-19: a systematic review and detailed comprehension. Int J Neurosci 2023; 133: 754–769.

    OpenUrl
18. 18.↵
    1. Vahey GM,
    2. McDonald E,
    3. Marshall K,
    4. Martin SW,
    5. Chun H,
    6. Herlihy R, et al.

    Risk factors for hospitalization among persons with COVID-19-Colorado. PLoS One 2021; 16: e0256917.

    OpenUrlPubMed
19. 19.
    1. Ko JY,
    2. Danielson ML,
    3. Town M,
    4. Derado G,
    5. Greenlund KJ,
    6. Kirley PD, et al.

    Risk factors for coronavirus disease 2019 (COVID-19)-associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system. Clin Infect Dis 2021; 72: e695–e703.

    OpenUrlPubMed
20. 20.↵
    1. Alrashed AA,
    2. Khan TM,
    3. Alhusseini NK,
    4. Asdaq SM,
    5. Enani M,
    6. Alosaimi B, et al.

    Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study. J Infect Public Health 2021; 14: 726–733.

    OpenUrl
21. 21.↵
    1. Nassar M,
    2. Daoud A,
    3. Nso N,
    4. Medina L,
    5. Ghernautan V,
    6. Bhangoo H, et al.

    Diabetes Mellitus and COVID-19: review Article. Diabetes Metab Syndr 2021; 15: 102268.

    OpenUrl
22. 22.↵
    1. Blonde L,
    2. Umpierrez GE,
    3. Reddy SS,
    4. McGill JB,
    5. Berga SL,
    6. Bush M, et al.

    American association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 Update [Erratum in: Endocr Pract. 2023 Jan;29] [1] [:80-81. PMID: 35963508; PMCID: PMC10200071]. Endocr Pract 2022; 28: 923–1049.

    OpenUrl
23. 23.↵
    1. Rizvi AA,
    2. Kathuria A,
    3. Al Mahmeed W,
    4. Al-Rasadi K,
    5. Al-Alawi K,
    6. Banach M, et al.

    Post-COVID syndrome, inflammation, and diabetes. J Diabetes Complications 2022; 36: 108336.

    OpenUrlCrossRef
24. 24.↵
    1. Safar ME,
    2. Asmar R,
    3. Benetos A,
    4. Blacher J,
    5. Boutouyrie P,
    6. Lacolley P, et al.

    French study group on arterial stiffness. interaction between hypertension and arterial stiffness. Hypertension 2018; 72: 796–805.

    OpenUrl
25. 25.↵
    1. Chung MK,
    2. Zidar DA,
    3. Bristow MR,
    4. Cameron SJ,
    5. Chan T,
    6. Harding CV 3rd., et al.

    COVID-19 and cardiovascular disease: from bench to bedside. Circ Res 2021; 128: 1214–1236.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Messerli FH,
    2. Williams B,
    3. Ritz E

    . Essential hypertension. Lancet 2007; 370: 591–603.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Hippisley-Cox J,
    2. Young D,
    3. Coupland C,
    4. Channon KM,
    5. Tan PS,
    6. Harrison DA, et al.

    Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart 2020; 106: 1503–1511.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Agirbasli M

    . The effects of antihypertensive medications on severity and outcomes of COVID19. J Hum Hypertens 2022; 36: 875–879.

    OpenUrl
29. 29.↵
    1. Danser AH,
    2. Epstein M,
    3. Batlle D

    . Renin-angiotensin system blockers and the COVID-19 pandemic: At present there is no evidence to abandon renin-angiotensin system blockers. Hypertension 2020; 75: 1382–1385.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Barbé-Tuana F,
    2. Funchal G,
    3. Schmitz CR,
    4. Maurmann RM,
    5. Bauer ME

    . The interplay between immunosenescence and age-related diseases. Semin Immunopathol 2020; 42: 545–557.

    OpenUrlCrossRef
31. 31.↵
    1. Murugan AT,
    2. Sharma G

    . Obesity and respiratory diseases. Chron Respir Dis 2008; 5: 233–242.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Al-Tammemi AB

    . Tobacco epidemic in Jordan: the time to act is now. Glob Health Promot 2022; 29: 97–101.

    OpenUrl
33. 33.↵
    1. Farsalinos K,
    2. Bagos PG,
    3. Giannouchos T,
    4. Niaura R,
    5. Barbouni A,
    6. Poulas K

    . Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication. Harm Reduct J 2021; 18: 9.

    OpenUrl
34. 34.↵
    1. Patanavanich R,
    2. Glantz SA

    . Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res 2020; 22: 1653–1656.

    OpenUrlCrossRefPubMed
35. 35.↵
    GOV.UK. Flu vaccines for the 2023 to 2024 season. [Updated 2023; Cited in 2023 June 3]. Available from: https://www.gov.uk/government/publications/flu-vaccines-for-the-current-season/flu-vaccines-for-the-2023-to-2024-season#eligible-groups [Accessed July 3, 2023]